Data/hora: 05/06/2024 05:37:10

Provedor de dados: 	55	
País: 	Brazil	
Título: 	Weight-based combination therapy with peginterferon alpha-2b and ribavirin for Naïve, relapser and non-responder patients with chronic hepatitis C	
Autores: 	Gonçales Jr.,Fernando Lopes; Vigani,Aline; Gonçales,Neiva; Barone,Antonio Alci; Araújo,Evaldo; Focaccia,Roberto; Oliveira,Umbeliana; Coelho,Henrique Sérgio Morais; Paixao,Jacqueline; Perez,Renata; Lobato,Cirley; Weirich,Judith; Rosa,Heitor; Borges,Andrelina; Vila,Ricardo; Corrêa-Giannella,Maria Lúcia; Ferraz,Maria Lúcia Gomes.	
Data: 	2006-10-01	
Ano: 	2006	
Palavras-chave: 	Hepatitis C; Interferon alpha-2b; Therapy.	
Resumo: 	Combination therapy with pegylated interferon and ribavirin is considered the new standard therapy for naïve patients with chronic hepatitis C. We evaluated the efficacy and safety of treatment with weight-based peginterferon alpha-2b (1.5 mg/kg per week) plus ribavirin (800-1,200 mg/day) for 48 weeks in naïve, relapser and non-responder (to previous treatment with interferon plus ribavirin) patients with chronic hepatitis C. Sixty-seven naïve, 26 relapser and 40 non-responder patients were enrolled. The overall sustained virological response (SVR) for the intention-to-treat population was 54% for naïve, 62% for relapser and 38% for non-responder patients. In the naïve subgroup, SVR was significantly higher in patients with the non-1 genotype (67%) compared to those with genotype 1 (45%). In relapsers and non-responders, SVR was, respectively, 69% and 24% in patients with genotype 1 and 43% and 73% in those with genotype non-1. There were no significant differences in SVR rates among the three body weight ranges (&lt; 65 kg, 65-85 kg and &gt; 85 kg) in any of the subgroups. Early virological response (EVR) was reached by 78%, 81% and 58% of naïve, relapser and non-responder patients, respectively, and among those with EVR, 63%, 67% and 61%, respectively, subsequently achieved SVR. All of the non-responder patients who did not have EVR reached SVR. Treatment was discontinued in 13% of the patients, due to loss to follow-up, hematological abnormalities or depression.	
Tipo: 	Info:eu-repo/semantics/article	
Idioma: 	Inglês	
Identificador: 	http://www.scielo.br/scielo.php?script=sci_arttext&pid=S1413-86702006000500002	
Editor: 	Brazilian Society of Infectious Diseases	
Relação: 	10.1590/S1413-86702006000500002	
Formato: 	text/html	
Fonte: 	Brazilian Journal of Infectious Diseases  v.10 n.5 2006	
Fonte: 	info:eu-repo/semantics/openAccess